Rubin Steven D 4

What Happened
Steven D. Rubin, a director of Niagen Bioscience, was granted derivative securities representing 31,746 shares on June 24, 2026. The reported acquisition price is $0.00 (derivative award/option); the grant itself did not involve a sale or exercise and no cash was reported as paid.

Key Details

• Transaction date: June 24, 2026; Filing date: June 26, 2026 (Form 4 accession 0001381874-26-000001) — appears to be filed within the standard Form 4 window.
• Securities: 31,746 derivative shares granted; reported price: $0.00.
• Vesting: Option vests 100% on June 24, 2027 (footnote).
• Shares owned after transaction: not specified in the filing.
• Transaction code: A (grant/award/acquisition of derivative securities).

Context
This was a grant of derivative securities (an option/award) rather than a market purchase or sale. The award becomes exercisable in full on June 24, 2027; Rubin has not exercised or sold these shares as of the filing. Grants like this are common as director compensation and do not, by themselves, indicate buying or selling intent.